The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.
| Level | Code | Title | |
|---|---|---|---|
| 1 | N | Nervous system | |
| 2 | N04 | Anti-parkinson drugs | |
| 3 | N04B | Dopaminergic agents | |
| 4 | N04BA | Dopa and dopa derivatives |
| Code | Title | |
|---|---|---|
| N04BA01 | Levodopa | |
| N04BA02 | Levodopa and decarboxylase inhibitor | |
| N04BA03 | Levodopa, decarboxylase inhibitor and COMT inhibitor | |
| N04BA04 | Melevodopa | |
| N04BA05 | Melevodopa and decarboxylase inhibitor | |
| N04BA06 | Etilevodopa and decarboxylase inhibitor | |
| N04BA07 |
| Active Ingredient | Description | |
|---|---|---|
| Levodopa |
According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease. |
| Title | Information Source | Document Type | |
|---|---|---|---|
| CORBILTA Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC | |
| INBRIJA Inhalation powder, capsule | FDA, National Drug Code (US) | MPI, US: SPL/PLR | |
| LEVOMED Tablet | Υπουργείο Υγείας (CY) | MPI, EU: SmPC | |
| MADOPAR Capsule, Rapid dispersible tablet | Medicines and Medical Devices Safety Authority (NZ) | MPI, EU: SmPC | |
| STALEVO Film-coated tablet | European Medicines Agency (EU) | MPI, EU: SmPC |
